|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0034975,
umls-concept:C0072348,
umls-concept:C0155626,
umls-concept:C0205225,
umls-concept:C0233820,
umls-concept:C0247025,
umls-concept:C1418370,
umls-concept:C1514496,
umls-concept:C1549071,
umls-concept:C1705930,
umls-concept:C1707455,
umls-concept:C2347515
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2011-2-8
|
|
pubmed:abstractText |
Despite the proven benefit of glycoprotein IIb/IIIa blockers in patients with acute ST-segment elevation myocardial infarction (STEMI), there is still debate on the timing of administration of these drugs and whether all or only a selection of patients should be treated. We evaluated the effect of routine upfront versus provisional use of high-dose tirofiban (HDT) in a large real-world population of non-selected STEMI patients.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-11919304,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-14660991,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-15827315,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-16908490,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-18371475,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-18455217,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-18474534,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-18499565,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-18499566,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-18707985,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-19004841,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-19378689,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-19682233,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-19755402,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-3109764,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21301621-8813982
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:status |
PubMed-not-MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1876-6250
|
|
pubmed:author |
pubmed-author:DambrinkJ-H EJH,
pubmed-author:GosselinkA T MAT,
pubmed-author:HeestermansA A C MAA,
pubmed-author:HermanidesR SRS,
pubmed-author:HoorntjeJ C AJC,
pubmed-author:KolkmanEE,
pubmed-author:OttervangerJ PJP,
pubmed-author:SuryapranataHH,
pubmed-author:Ten BergJ MJM,
pubmed-author:ZijlstraFF,
pubmed-author:de BoerM JMJ,
pubmed-author:van 't HofA W JAW
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
592-7
|
|
pubmed:dateRevised |
2011-7-25
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI: Insights from the Zwolle acute myocardial infarction registry.
|
|
pubmed:affiliation |
Department of Cardiology, Medical Centre Alkmaar, Alkmaar, the Netherlands.
|
|
pubmed:publicationType |
Journal Article
|
